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Introduction: Assessment of functional capacity is an intrinsic part of determining the functional relevance of
response to treatment of cognitive impairment in schizophrenia. Existing methods are highly and consistent-
ly correlated with performance on neuropsychological tests, but most current assessments of functional ca-
pacity are still paper and pencil simulations. We developed a computerized virtual reality assessment that
contains all of the components of a shopping trip.
Methods:We administered the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) to 54 healthy con-
trols and to 51peoplewith schizophrenia to test its feasibility. Dependent variables for theVRFCAT included time
to completion and errors on 12 objectives and the number of times that an individual failed to complete an
objective. The MATRICS Consensus Cognitive Battery (MCCB) and a standard functional capacity measure, the
UCSD Performance-Based Skills Assessment-Brief (UPSA-B), were administered to the patients with schizophrenia.
Results: Patients with schizophrenia performed more poorly than healthy controls on 10/11 of the time variables,
as well as 2/12 error scores and 2/12 failed objectives. Pearson correlations for 7 of 15 VRFCAT variables withMCCB
composite scores were statistically signiﬁcant.
Conclusion: These results provide support for the possibility of computerized functional capacity assessment, but
more substantial studies are required.© 2014 Elsevier Inc. All rights reserved.1. Introduction
Schizophrenia is marked by substantial impairments in everyday
functioning in multiple domains (Harvey and Bowie, 2005). Achieve-
ment of functional milestones in areas such as full-time employment,
independence in residence, and social functioning is reduced com-
pared to both healthy people and other severe mental illnesses such
as bipolar disorder (Harvey et al., 2010). Candidates for the causes
of these impairments include cognitive deﬁcits, impairments in the
ability to perform the skills required to achieve success in everyday,
negative symptoms and depression, health variables, and a variety
of social, cultural, and environmental factors.
A recent development in research on the determinants of dis-
ability in schizophrenia has been performance- (Harvey et al.,
2007) and interview-based (Keefe et al., 2006) measures of Func-
tional Capacity (FC). Studies of performance-based assessments ofRuse).
rights reserved.FC have found that impairments on these measures predict failures
to achieve milestones in vocational, residential, and social domains
(Mausbach et al., 2010; Mausbach et al., 2013) in schizophrenia and
bipolar disorder populations (Bowie et al., 2010; Depp et al., 2012).
Whether everyday functioning is deﬁned either by milestone
achievement (Gould et al., 2012) or by ratings generated by high-
contact informants (Bowie et al., 2008), impairments on measures
of FC have typically been found to be more proximal to everyday
functional deﬁcits than cognitive impairments. Further, the correla-
tion between performance on FC measures and neuropsychological
(NP) tests has been remarkably consistent and substantial, typically
r = 0.60 or greater (Leifker et al., 2011).
The importance of valid and efﬁcient assessment of FC has been
increased by the requirement of the US Food and Drug Administration
(FDA) that all studies attempting to demonstrate improvements in
cognitive functioning induced by pharmacological or cognitive reme-
diation means also provide evidence of functional relevance by “co-
primary” measures (Buchanan et al., 2005; Buchanan et al., 2010).
In a study of people with schizophrenia, performance-based
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sessment (UPSA; Patterson et al., 2001) and the Test of Adaptive Be-
havior in Schizophrenia (TABS; Velligan et al., 2007), demonstrated
substantially higher correlations with NP test performance than
patient self-reports derived from interview-based measures (Green
et al., 2011). Although use of high-contact informants, particularly cli-
nicians, yields correlations with NP performance consistent with
performance-based measures of FC (Keefe et al., 2006), many people
with schizophrenia may not have access to high-contact clinicians
(Patterson et al., 1997) and the use of informants other than close-
contact caregivers or clinicians may yield questionable results
(Poletti et al., 2012; Sabbag et al., 2011).
Functional capacity measures have also demonstrated high levels
of test-retest reliability, minimal practice effects, and minimal miss-
ing data in large-scale clinical trials (Keefe et al., 2011). Despite
these multiple strong features, there are some limitations to the cur-
rent set of FC measures. These measures are delivered in a paper and
pencil format, which is not practical for remote delivery or for simul-
taneous assessment of multiple cases. With the advent of remotely
deliverable cognitive remediation therapy (CRT), in-person assess-
ment of functional gains may not always be possible. Further, these
measures are comprised of several functional tasks that are not re-
quired consistently across different cultures and do not have alternate
forms (Velligan et al., 2012).
In an attempt to enhance the assessment of FC we have developed
a computerized, immersive, and potentially remotely deliverable FC
assessment referred to as the Virtual Reality Functional Capacity As-
sessment Tool (VRFCAT). The VRFCAT consists of a tutorial and 6 ver-
sions of 4 mini scenarios that include navigating a kitchen and
planning a trip to the grocery store, catching a bus to a grocery
store (selecting the correct bus and paying the correct fare), purchas-
ing food at the grocery store, and returning home on a bus. Thus, this
assessment strategy captures several of the functional domains of
other FC measures: transportation, ﬁnances, household management,
and planning. Further, the alternate forms are a unique feature of this
assessment and the scenarios have the potential to be rapidly
updated and cross-culturally adapted.
There have been previous efforts made to create computerized
FC assessments. There is a long history of these tasks being used
in aging populations in order to simulate functional demands that
include either use of computer or interactive voice menus (Czaja
and Sharit, 2003). Computerized FC assessments have also previ-
ously been employed in schizophrenia. For instance, a computer-
ized version of the UPSA was recently developed, although this
assessment currently requires an in-person examiner (Moore
et al., 2013). Virtual reality assessments aimed at delusions of per-
secution have been developed as well (Freeman, 2008). Further,
Kurtz et al. (2007) developed a medication management assess-
ment with a virtual apartment. These previous assessments are dif-
ferent from the current one because of the sequential, multi-task
demands of a simulated shopping trip and the goal of wide cover-
age of functional domains in the VRFCAT.
In this paper we present the preliminary results from the develop-
ment and initial feasibility study of the VRFCAT. The VRFCAT was ad-
ministered to both healthy individuals and people with
schizophrenia. In addition, schizophrenia patients were assessed
with the MATRICS Consensus Cognitive Battery (MCCB) and the
UCSD Performance-Based Skills Assessment-Brief (UPSA-B). This
study was conducted in sequence, with the healthy control (HC)
group assessed ﬁrst in order to understand the feasibility of the task
and the schizophrenia patients examined later. Therefore, the samples
were not selected to be “matched” on demographics and there are
some differences between the samples. Our analyses examined the
differences in performance between the HC group and people with
schizophrenia, as well as the correlations between a standard paper
and pencil functional capacity measure (UPSA-B), cognitiveperformance (composite scores on a modiﬁed version of the MCCB),
and performance on the VRFCAT in people with schizophrenia.
2. Methods
2.1. Subjects
Two different samples of subjects were compared. During the de-
velopment phase, 102 healthy controls from Durham, North Carolina,
were recruited. As this was a feasibility study only, a formal assess-
ment of psychopathology was not performed although subjects
were asked if they had received previous mental health treatment.
The subjects were tested with 1 of 6 randomly selected versions of
the assessment and then asked to return for re-test with a different
randomly selected version 7–14 days later. All research participants
provided signed, informed consent, and this research study was ap-
proved by the Western IRB. Healthy control subjects received
$20.00 per visit for their time and effort in completing the VRFCAT.
Ninety of those 102 returned for testing with a different version of
the application. Due to an initial data management problem that
was later rectiﬁed, only 69 of the 90 who returned had complete
data sets. During our initial analysis of the data, two application errors
were identiﬁed: First, we observed that one of the versions of the
VRFCAT yielded signiﬁcantly outlying data and did not perform in
an equitable way to the other versions. As a result, we excluded this
version from all subsequent analyses. Second, we identiﬁed a pro-
gramming error resulting in inaccurate collection of the time to com-
plete Objective 12. This variable was therefore excluded from
subsequent analyses. In addition, two signiﬁcant outliers were dis-
covered and removed from data analysis, resulting in a HC sample
size of n = 54.
The patient sample was collected from one of the two sites partic-
ipating in the Validation of Everyday Real-world Outcomes (VALERO)
study, phase 2. All patients were recruited and assessed at the Univer-
sity of Miami Miller School of Medicine. All patients provided signed,
informed consent, and this research study was approved by the local
IRB. During the initial analysis of the data, one signiﬁcant outlier was
discovered and removed. In addition, four patients were removed
from analysis due to rater administration errors, resulting in a patient
sample size of n = 51.
All patients with schizophrenia were administered the Structured
Clinical Interview for the DSM-IV (SCID; First et al., 1995) by a trained
interviewer, and diagnoses were subjected to a consensus procedure.
Participants were excluded if they had a history of traumatic brain in-
jury with unconsciousness N10 minutes, brain disease such as seizure
disorder or neurodegenerative condition, or the presence of any DSM-
IV-TR diagnosis on Axis I that would exclude the diagnosis of schizo-
phrenia. None of the patients were experiencing their ﬁrst psychotic
episode. In order to capture a broad array of patients, substance
abuse was not an exclusion criterion for patients but anyone who
appeared intoxicated was rescheduled. Inpatients were not recruited,
but patients resided in an assortment of unsupported, supported, or
supervised residential locations. Patients received $25.00 for their
time and effort above and beyond their compensation for participa-
tion in VALERO-II.
2.1.1. Procedure
All participants were examined with the VRFCAT. All patients
were also examined with a performance-based assessment of NP abil-
ities and FC. The VRFCAT was administered to patients after comple-
tion of a comprehensive assessment of a variety of aspects of
cognition and everyday functioning, which is partially reported here.
2.1.2. VRFCAT description
The VRFCAT was developed in order to measure four different
functional abilities: checking for the availability of items to complete
Table 1
VRFCAT objectives.
Objective Description
1 Pick-up the recipe
2 Search for ingredients
3 Cross off correct ingredients & pick-up bus schedule
4 Pick-up the billfold
5 Exit the apartment
6 Get on the bus to the grocery store
7 Pay for the bus
8 Select an aisle
9 Shop for groceries
10 Pay for groceries
11 Get on the bus to go home
12 Pay for the bus
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These scenarios were developed using immersive virtual reality
(VR) technology. All participants received a brief tutorial, which in-
cluded sample items similar to those from the test and practice in
using the mouse and computer prior to their assessment. There
were 12 different objectives, presented in Table 1. For each objective,
the dependent variables were accuracy of performance and time to
completion. For all objectives, participants who were unable to com-
plete the objective within a pre-speciﬁed time period or without
making a certain number of errors were automatically progressed to
the next objective.0
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Fig. 1. Average number of errors and time for patie2.2. Performance-based assessment for patients
2.2.1. Neurocognition
We examined NP performance with a modiﬁed version of the
MCCB (Nuechterlein et al., 2008). For this study, the MSCEIT social
cognition measure was not included, as the VALERO investigators
were interested in variables that were purely neurocognitive, and
there is evidence that social cognition and neurocognition may be
separate constructs (Ventura et al., 2013). We calculated the compos-
ite score generated by the MCCB computer program, which is based
on 6 of the 7 domain scores, excluding social cognition. See Kern
et al. (2011) for a description of the typical patterns of impairment
seen in schizophrenia patients on the MCCB.
In addition to the modiﬁed version of the MCCB, participants in
the patient group completed the Wide-Range Achievement Test, 3rd
edition (WRAT-3; Wilkinson, 1993). This was done to ensure that
all patients could read adequately to be assessed with the cognitive
battery and also as an approximate index of intellectual functioning.
Cases who received scores at less than the 6th grade level were ex-
cluded prior to any other assessments.
2.2.2. Functional capacity
Patients’ FC was assessed using the Brief version of the UCSD
Performance-Based Skills Assessment (UPSA-B; Mausbach et al.,
2008). The UPSA-B is a measure of FC in which patients are asked to
perform everyday tasks related to communication and ﬁnances. During
the Communication subtest, participants are required to role-play9 10 11 12
n VRFCAT Objectives 
Healthy Controls 
Schizophrenia Patients
Healthy Controls
9 10 11 12
on VRFCAT Objectives 
 Healthy Controls 
Schizophrenia Patients
Healthy Controls
nts and healthy controls on VRFCAT objectives.
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number from memory; calling to reschedule a doctor’s appointment).
For the Finance subtest, participants are required to count change,
read a utility bill, and write a check for the bill. The UPSA-B requires ap-
proximately 10–15 minutes to complete, and raw scores are converted
into a total score ranging from 0–100, with higher scores indicating bet-
ter FC. Recently Green et al. (2011) reported that the UPSA-Bwas deter-
mined to be the most suitable short form of the available FC
assessments as a co-primary measure in clinical treatment trials.3. Results
The HC sample had more females than the schizophrenia sample
(65% versus 31%). The schizophrenia patients were 51% African Amer-
ican, 35% Hispanic, and 12% Caucasian, while the HC sample were 39%
African American and 59% Caucasian. Each sample had one partici-
pant of Asian descent. The ages of the samples were similar, with
the schizophrenia sample’s age averaging 39.7 (SD = 11.95) and
the HC group averaging 37.6 (SD = 12.48).
There are three aspects of performance on the 12 objectives that
were examined and compared across groups: time to complete
each objective, errors made on each objective, and number of times
that the task was progressed to the next objective because the previ-
ous one was not completed in a timely manner. As can be seen in
Fig. 1, the schizophrenia patients performed signiﬁcantly more
slowly than controls on 10 of the 11 objectives with valid data and
made signiﬁcantly more errors on 2 of the 8 objectives with total er-
rors greater than 0. As seen in the ﬁgure, the distributions of times
and errors were quite similar for the HC group and patients, with no
evidence of a global performance deﬁcit across all objectives on the
part of the schizophrenia patients. Table 2 presents the statistical
tests of the differences between healthy controls and patients across
the 12 objectives for time, errors, and forced progressions. Note that
for every variable on which the HC and SCZ groups differed by
p b 0.05, the differences would have met the Bonferroni correction
for multiple corrections.
Next we examined the extent to which performance on different
objectives discriminated the groups. For this analysis, which is intrin-
sically exploratory, we entered the variables which signiﬁcantly dis-
criminated the two groups in the domains of times, errors, and
forced progressions from Table 2, as well as the numbers of times
the recipe was accessed, with α-level for entry set to 0.15 and α-
level for remaining in the model set to 0.10. We selected items that
were signiﬁcant in a forward entry stepwise regression analysis and
examined classiﬁcation accuracy as well as variance contributed to
discrimination. The ﬁnal model yielded the 8 variables presented in
Table 3. Time and errors for getting on the bus home as well as timeTable 2
Differences between healthy controls and schizophrenia patients on the twelve VRFCAT ob
Time to completion
T statistic p value
1. Pick-up the recipe 3.66 b0.001
2. Search for ingredients 3.52 b0.001
3. Cross off correct ingredients & pick-up bus schedule 5.65 b0.001
4. Pick-up the billfold 5.81 b0.001
5. Exit the apartment 3.31 0.001
6. Get on the bus to the grocery store 4.76 b0.001
7. Pay for the bus 3.73 b0.001
8. Select an aisle 2.96 0.004
9. Shop for groceries 7.00 b0.001
10. Pay for groceries 3.19 0.002
11. Get on the bus to go home 9.04 b0.001
12. Pay for the bus ⁎⁎ ⁎⁎
⁎ Based on Fisher's exact test.
⁎⁎ Data not collected.to pick up the billfold each contributed more than 10% variance to
the canonical discriminant function. Classiﬁcation accuracy was out-
standing, with all 51 of the schizophrenia patients correctly classiﬁed
and 53 out of 54 HC participants correctly classiﬁed as well.
In order to examine other potential inﬂuences on performance, we
correlated age with summary variables from errors, time, and forced
progressions on the VRFCAT in each sample separately. For the
schizophrenia patients, total errors (r = 0.47), total time (r = 0.53)
and total progressions (r = 0.52) were all statistically signiﬁcant
with p values b0.001. In the HC sample, the correlations were notice-
ably smaller, total errors (r = 0.10), total time (r = 0.17), and total
progressions (r = 0.09), and did not achieve statistical signiﬁcance
(all p values N0.20).
We also examined the correlations between MCCB scores, UPSA-B
scores, and three aspects of performance on the VRFCAT objectives. In
this analysis, we selected the individual VFRCAT variables that discrim-
inated between HC and schizophrenia patients, as well as the three
VRFCAT summary variables, and correlated themwith theMCCB cogni-
tive composite and the UPSA-B total score. These correlations are
presented in Table 4. As can be seen in the table, a number of the indi-
vidual variables and summary scores for errors, time, and progression
were correlated with the MCCB cognitive composite. Interestingly, in
this preliminary study, there were no signiﬁcant correlations between
VRFCAT performance and any of the scores on the UPSA-B.
In a ﬁnal descriptive analysis, we examined the total variance
shared between the VRFCAT items and theMCCB cognitive composite.
Using a forward entry stepwise regression, with a liberal criterion of
p b 0.10 to enter, we found the following variables entered, in order,
from the biggest to smallest contribution to total variance accounted
for: errors while shopping, time to pick up the recipe, time to pay for
groceries, and time to pay for the bus. The overall regression was sta-
tistically signiﬁcant with these four variables entered, F(4,46) = 6.82,
p b 0.001, and the shared variance between the MCCB cognitive com-
posite and these four outcome variables was R2 = 0.37.4. Discussion
The assessment of functional capacity with virtual reality method-
ology in people with schizophrenia is feasible with the proportion of
patients able to complete the assessment in a valid manner consistent
with healthy controls. There is evidence that patients perform more
poorly on several aspects of the task than healthy controls, without
demonstrating evidence of global deﬁcits on every element of the
task. The parts of the task that were performed most poorly suggest
slowing in the performance of information processing and working
memory. In line with this ﬁnding, VRFCAT performance in schizo-
phrenia patients was correlated with performance on the MCCB.jectives.
# of Errors Forced progression frequency
T statistic p value Healthy control Patient p value⁎
1.07 0.285 0 0 -
1.03 0.306 0 1 0.4857
3.60 b0.001 7 21 0.0017
0.04 0.968 0 0 -
- - 0 0 -
1.71 0.090 0 0 -
0.72 0.472 0 0 -
- - 0 0 -
2.66 0.009 3 13 0.0059
1.57 0.120 0 2 0.2334
1.85 0.072 0 0 -
1.12 0.264 1 2 0.611
Table 3
Results of the discriminant function comparing the two groups of study subjects.
Order of entry Objective Partial R-square F p-value
1 Time to catch the bus home 0.442 81.64 b0.001
2 # Errors made catching the bus home 0.308 45.29 b0.001
3 Time to pick up the billfold 0.132 15.40 b0.001
4 Time to pick up the recipe 0.081 8.84 0.004
5 Time to exit the apartment 0.046 4.75 0.032
6 # Errors made catching the bus to the grocery store 0.040 4.13 0.045
7 Forced Progression while shopping for groceries 0.045 4.53 0.036
8 # Times the recipe was accessed 0.036 3.55 0.063
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measure. There were no signiﬁcant correlations of the VRFCAT total
scores with performance on the UPSA-B, indicating that the VRFCAT
and UPSA-B seem to be measuring different aspects of functional def-
icits. Further research will more systematically evaluate the relation-
ships between the VRFCAT and other potential co-primary measures,
as well as performing a more suitable normative understanding of the
differences between HC and patients with schizophrenia on this task.
There are some limitations in this study. Our healthy controls
were tested ﬁrst, as part of the development process of the VRFCAT,
and as a result some participants were excluded because of problems
with an earlier, immature version of the task. Educational attainment
for the healthy controls was not measured systematically. The schizo-
phrenia patients were not selected for representativeness to any pre-
speciﬁed group of patients, other than all participants being willing
and able to participate in an extended assessment similar to those
seen in a schizophrenia treatment trial. Gender and racial ethnic dif-
ferences in the samples were present. Given the small sample sizes,
there are no normative statements about performance that can beTable 4
Pearson Correlations between VRFCAT Variables and MCCB and UPSA-B performance in
Schizophrenia Patients.
MCCB cognitive
composite
UPSA-B total score
Time to pick-up the recipe −0.40 (0.004) −0.22 (0.123)
Time to search for ingredients 0.10 (0.497) −0.05 (0.748)
Time to cross off correct
ingredients & pick-up
bus schedule
−0.24 (0.088) −0.15 (0.307)
Time to pick-up the billfold −0.00 (0.981) 0.27 (0.055)
Time to exit the apartment −0.35 (0.011) −0.22 (0.128)
Time to get on the bus to
the grocery store
−0.04 (0.760) −0.02 (0.895)
Time to pay for the bus −0.23 (0.109) −0.08 (0.596)
Time to select an aisle 0.05 (0.718) 0.09 (0.513)
Time to shop for groceries −0.33 (0.018) −0.15 (0.293)
Time to pay for groceries −0.01 (0.936) 0.06 (0.699)
Time to get on the bus to
go home
−0.21 (0.148) −0.22 (0.114)
Time to pay for the bus −0.37 (0.007) −0.19 (0.180)
# Errors crossing off correct
ingredients & picking-up
bus schedule
−0.16 (0.277) −0.13 (0.366)
# Errors getting on the bus to
the grocery store
−0.32 (0.021) −0.11 (0.440)
# Errors shopping for groceries −0.41 (0.003) −0.20 (0.164)
# Errors getting on the bus
to go home
−0.21 (0.138) −0.18 (0.205)
# Forced progressions when
crossing off correct ingredients
& picking-up bus schedule
−0.23 (0.111) −0.06 (0.662)
# Forced progressions when
shopping for groceries
−0.41 (0.003) −0.14 (0.325)
# Times the recipe was accessed 0.09 (0.526) −0.22 (0.116)
Total time −0.28 (0.045) −0.14 (0.322)
Total errors −0.36 (0.009) −0.21 (0.142)
Total forced progressions −0.29 (0.036) −0.07 (0.605)
Global performance composite 0.32 (0.023) 0.14 (0.335)made and we cannot inquire about test-retest stability or the stability
of correlations between the MCCB, UPSA-B, and VRFCAT in the cur-
rent data set. These issues are being addressed comprehensively in
an on-going study with substantial statistical power.
Our study does suggest that computerized functional capacity
tests are feasible in schizophrenia patients and correlated with
MCCB scores. The VRFCAT runs on standard operating systems and
does not require specialized equipment such as a touch screen.
Thus, the potential for remote deliverability is clear. Research is cur-
rently ongoing to more systematically examine the VRFCAT’s psycho-
metric properties in a much larger sample, including test-retest
stability, deliverability across multiple sites, more extensive norma-
tive comparisons to healthy controls, and stability of correlations be-
tween MCCB and VRFCAT performance over time.
Role of Funding Source
This work was supported by the National Institute of Mental Health
Grant Number 1 R43MH0842-01A2 awarded to Dr. Keefe and Dr.
Fox, the National Institute of Mental Health Grant Number 2
R44MH084240-02 awarded to Dr. Keefe and Dr. Atkins, and Grant
Number MH 78775 awarded to Dr. Harvey.
Contributors
Stacy A. Ruse assisted in the development of the VRFCAT, collected
data, and drafted the manuscript. Philip D. Harvey assisted in the de-
velopment of the VRFCAT and in editing and writing this paper. Vicki
G. Davis analyzed the data for this paper. Alexandra S. Atkins assisted
in editing this paper. Kolleen H. Fox assisted in the development of the
VRFCAT, supervised data collection, and editing this paper. Richard
S.E. Keefe supervised the development of the VRFCAT, oversaw data
collection and assisted in editing this paper.
Conﬂict of interest
The author, Stacy A. Ruse, is an employee of NeuroCog Trials, Inc. The
author, Philip D. Harvey, is a Professor of Psychiatry & Behavioral Sci-
ences, Chief, Division of Psychology, Department of Psychiatry & Be-
havioral Sciences, University of Miami Miller School of Medicine and
Senior Clinical Research Scientist, Miami Veterans Affairs Healthcare
System. The author, Vicki G. Davis, is an employee of NeuroCog Trials,
Inc. The author, Alexandra S. Atkins, is an employee of NeuroCog Tri-
als, Inc. The author, Kolleen H. Fox is a former employee of NeuroCog
Trials, Inc. The author, Richard S.E. Keefe, is the Founder and CEO of
NeuroCog Trials, Inc. and a Professor of Psychiatry Behavioral Sciences
at Duke University Medical Center.
Acknowledgments
We thank the staff at the University of Miami Miller School of Medi-
cine who completed the data collection for the VALERO study.
References
Bowie, C.R., Depp, C., McGrath, J.A., Wolyniec, P., Mausbach, B.T., Thornquist, M.H.,
Luke, J., Patterson, T.L., Harvey, P.D., Pulver, A.E., 2010. Prediction of real-world
e26 S.A. Ruse et al. / Schizophrenia Research: Cognition 1 (2014) e21–e26functional disability in chronic mental disorders: A comparison of schizophrenia
and bipolar disorder. Am. J. Psychiatry 167 (9), 1116–1124.
Bowie, C.R., Leung, W.W., Reichenberg, A., McClure, M.M., Patterson, T.L., Heaton, R.K.,
Harvey, P.D., 2008. Predicting schizophrenia patients’ real-world behavior with
speciﬁc neuropsychological and functional capacity measures. Biol. Psychiatry 63
(5), 505–511.
Buchanan, R.W., Davis, M., Goff, D., Green, M.F., Keefe, R.S., Leon, A.C., Nuechterlein,
K.H., Laughren, T., Levin, R., Stover, E., 2005. A summary of the FDA-NIMH-
MATRICS workshop on clinical trial design for neurocognitive drugs for schizo-
phrenia. Schizophr. Bull. 31 (1), 5–19.
Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A.,
Himelhoch, S., Fang, B., Peterson, E., Aquino, P.R., 2010. The 2009 schizophrenia
PORT psychopharmacological treatment recommendations and summary state-
ments. Schizophr. Bull. 36 (1), 71–93.
Czaja, S.J., Sharit, J., 2003. Practically relevant research: capturing real world tasks, en-
vironments, and outcomes. Gerontologist 43 (suppl 1), 9–18.
Depp, C.A., Mausbach, B.T., Harmell, A.L., Savla, G.N., Bowie, C.R., Harvey, P.D., Patterson,
T.L., 2012. Meta‐analysis of the association between cognitive abilities and every-
day functioning in bipolar disorder. Bipolar Disord. 14 (3), 217–226.
First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B., 1995. The structured clinical inter-
view for DSM-III-R personality disorders (SCID-II). part I: Description. J. Personal
Disord. 9 (2), 83–91.
Freeman, D., 2008. Studying and treating schizophrenia using virtual reality: A new
paradigm. Schizophr. Bull. 34 (4), 605–610.
Gould, F., Bowie, C.R., Harvey, P.D., 2012. The inﬂuence of demographic factors on func-
tional capacity and everyday functional outcomes in schizophrenia. J. Clin. Exp.
Neuropsychol. 34 (5), 467–475.
Green, M.F., Schooler, N.R., Kern, R.S., Frese, F.J., Granberry, W., Harvey, P.D., Karson,
C.N., Peters, N., Stewart, M., Seidman, L.J., 2011. Evaluation of functionally mean-
ingful measures for clinical trials of cognition enhancement in schizophrenia.
Am. J. Psychiatry 168 (4), 400–407.
Harvey, P., Bowie, C., 2005. Late-life schizophrenia. What providers need to know. Di-
rector 13(2), 90, 93–94.
Harvey, P.D., Velligan, D.I., Bellack, A.S., 2007. Performance-based measures of functional
skills: Usefulness in clinical treatment studies. Schizophr. Bull. 33 (5), 1138–1148.
Harvey, P.D., Wingo, A.P., Burdick, K.E., Baldessarini, R.J., 2010. Cognition and disability
in bipolar disorder: Lessons from schizophrenia research. Bipolar Disord. 12 (4),
364–375.
Keefe, R.S., Fox, K.H., Harvey, P.D., Cucchiaro, J., Siu, C., Loebel, A., 2011. Characteristics
of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophre-
nia clinical trial. Schizophr. Res. 125 (2), 161–168.
Keefe, R.S., Poe, M., Walker, T.M., Harvey, P.D., 2006. The relationship of the Brief As-
sessment of Cognition in Schizophrenia (BACS) to functional capacity and real-
world functional outcome. J. Clin. Exp. Neuropsychol. 28 (2), 260–269.
Kern, R.S., Gold, J.M., Dickinson, D., Green, M.F., Nuechterlein, K.H., Baade, L.E., Keefe,
R.S., Mesholam-Gately, R.I., Seidman, L.J., Lee, C., 2011. The MCCB impairment pro-
ﬁle for schizophrenia outpatients: Results from the MATRICS psychometric and
standardization study. Schizophr. Res. 126 (1), 124–131.Kurtz, M.M., Baker, E., Pearlson, G.D., Astur, R.S., 2007. A virtual reality apartment as a
measure of medication management skills in patients with schizophrenia: A pilot
study. Schizophr. Bull. 33 (5), 1162–1170.
Leifker, F.R., Patterson, T.L., Heaton, R.K., Harvey, P.D., 2011. Validating measures of
real-world outcome: The results of the VALERO expert survey and RAND panel.
Schizophr. Bull. 37 (2), 334–343.
Mausbach, B.T., Bowie, C.R., Harvey, P.D., Twamley, E.W., Goldman, S.R., Jeste, D.V.,
Patterson, T.L., 2008. Usefulness of the UCSD Performance-Based Skills Assessment
(UPSA) for predicting residential independence in patients with chronic schizo-
phrenia. J. Psychiatr. Res. 42 (4), 320–327.
Mausbach, B.T., Harvey, P.D., Pulver, A.E., Depp, C.A., Wolyniec, P.S., Thornquist, M.H., Luke,
J.R., McGrath, J.A., Bowie, C.R., Patterson, T.L., 2010. Relationship of the Brief UCSD Per-
formance‐based Skills Assessment (UPSA‐B) to multiple indicators of functioning
in people with schizophrenia and bipolar disorder. Bipolar Disord. 12 (1), 45–55.
Mausbach, B.T., Moore, R.C., Davine, T., Cardenas, V., Bowie, C.R., Ho, J., Jeste, D.V.,
Patterson, T.L., 2013. The use of the Theory of Planned Behavior to predict engage-
ment in functional behaviors in schizophrenia. Psychiatry Res. 205 (1–2), 36–42.
Moore, R.C., Harmell, A.L., Ho, J., Patterson, T.L., Eyler, L.T., Jeste, D.V., Mausbach, B.T.,
2013. Initial validation of a computerized version of the UCSD Performance-
Based Skills Assessment (C-UPSA) for assessing functioning in schizophrenia. Psy-
chiatry Res. 144 (1–3), 87–92.
Nuechterlein, K., Green, M., Kern, R., Baade, L., Barch, D., Cohen, J., Essock, S., Fenton, W.,
Frese, F., Gold, J., 2008. The MATRICS consensus cognitive battery, part 1: Test se-
lection, reliability, and validity. Am. J. Psychiatry 165 (2), 203–213.
Patterson, T.L., Goldman, S., McKibbin, C.L., Hughs, T., Jeste, D.V., 2001. UCSD
Performance-Based Skills Assessment: Development of a newmeasure of everyday
functioning for severely mentally ill adults. Schizophr. Bull. 27 (2), 235–245.
Patterson, T.L., Semple, S.J., Shaw, W.S., Halpain, M., Moscona, S., Grant, I., Jeste, D.V.,
1997. Self-reported social functioning among older patients with schizophrenia.
Schizophr. Res. 27 (2), 199–210.
Poletti, S., Anselmetti, S., Riccaboni, R., Bosia, M., Buonocore, M., Smeraldi, E., Cavallaro,
R., 2012. Self-awareness of cognitive functioning in schizophrenia: Patients and
their relatives. Psychiatry Res. 198 (2), 207–211.
Sabbag, S., Twamley, E.M., Vella, L., Heaton, R.K., Patterson, T.L., Harvey, P.D., 2011.
Assessing everyday functioning in schizophrenia: Not all informants seem equally
informative. Schizophr. Res. 131 (1), 250–255.
Velligan, D.I., Diamond, P., Glahn, D.C., Ritch, J., Maples, N., Castillo, D., Miller, A.L., 2007.
The Reliability and Validity of the Test of Adaptive Behavior in Schizophrenia
(TABS). Psychiatry Res. 151 (1–2), 55–66.
Velligan, D.I., Rubin, M., Fredrick, M.M., Mintz, J., Nuechterlein, K.H., Schooler, N.R.,
Jaeger, J., Peters, N.M., Buller, R., Marder, S.R., 2012. The cultural adaptability of in-
termediate measures of functional outcome in schizophrenia. Schizophr. Bull. 38
(3), 630–641.
Ventura, J., Wood, R.C., Hellemann, G.S., 2013. Symptom domains and neurocognitive
functioning can help differentiate social cognitive processes in schizophrenia: a
meta-analysis. Schizophr. Bull. 39 (1), 102–111.
Wilkinson, G.S., 1993. Wide Range Achievement Test: Third Edition. Wide Range, Wil-
mington, DE.
